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Abstract
Signaling by the transforming growth factor (TGF)-
family members is transduced from the cell surface to
the nucleus by the Smad group of intracellular
proteins. Because we detected alterations on the long
arm of chromosome 5, we examined the status of the
SMAD5 gene in human hepatocellular carcinoma
(HCC) cell lines and primary HCC. In 16 cell lines,
chromosome alterations of chromosome 5 were ob-
served in nine cell lines by fluorescence in situ
hybridization (FISH), and an increase in SMAD5 gene
copy number relative to the ploidy level was found in
eight lines. The breakpoints in unbalanced trans-
locations and deletions frequently occurred near the
SMAD5 locus, but apparently did not cause loss of
SMAD5. In one cell line, where comparative genomic
hybridization showed DNA copy number gain confined
to the region 5q31, we detected by FISH high-level
amplification of the SMAD5 gene located within the
fragile site FRA5C. Semiquantitative polymerase chain
reaction did not reveal changes in SMAD5 DNA levels
in 15 of 17 primary HCC specimens. In 17 HCC cell
lines, SMAD5 mRNA levels were either maintained or
upregulated by an increase in gene dosage or another
mechanism. Collectively, our results show that SMAD5
undergoes copy number gain and increased expres-
sion, rather than loss of expression, and therefore
suggest that this gene does not act as a tumor-
suppressor gene in HCC. The Hep-40 HCC cell line with
high-level amplification and significant overexpres-
sion of SMAD5 may be useful in studying the
interaction of SMAD5 with other genes.
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Introduction
Chromosomal translocations, inversions, deletions, and
amplifications contribute to the pathogenesis of human
cancer by affecting the expression of genes involved in
regulating cell growth [1–3]. Our characterization of recurrent
chromosome changes in human hepatocellular carcinoma
(HCC) at the molecular level is directed toward detecting
alterations of known genes and isolating new genes that may
be implicated in the development of liver neoplasia. From one
recurrent region of deletion on the short arm of chromosome
8 in HCC, we isolated the DLC-1 gene and recently showed
that it operates as a tumor suppressor in human breast cancers
[4,5]. Among known genes, we detected the deletion and
downregulation of the tumor-suppressor gene FHIT at 3p and
the amplification of the EMS1 oncogene at 11q, suggesting that
alterations of these genes are pathologically relevant to HCC
and might be useful markers for the early detection and
prognosis of the disease [6,7].
The transforming growth factor (TGF)-b family of cytokines
regulates a number of cellular processes, including prolifera-
tion, apoptosis, differentiation, and pattern formation [8]. Sig-
naling by members of the TGF-b family is transduced from the
cell surface to the nucleus by the Smad group of intracellular
proteins. Binding to receptors for the TGF-b family members
leads to the phosphorylation and activation of the receptor-
regulated Smads, which include Smads 1, 2, 3, 5, and 8 [8,9].
The activated Smads bind to the common mediator Smad4,
forming a complex that translocates to the nucleus and regu-
lates the transcription of target genes. TGF-b inhibits the
growth of many epithelial cells, and during the neoplastic
process, many carcinomas acquire resistance to the antiproli-
ferative signals of TGF-b [10]. In some tumors, the loss of TGF-
b responsiveness is associated with inactivation of one of the
components of the TGF-b signaling pathway, and mutations in
the SMAD4 and SMAD2 genes have been found in several
types of cancer [10,11].
Our previous comparative genomic hybridization (CGH)
studies and our ongoing spectral karyotyping (SKY) analyses
Abbreviations: HCC, hepatocellular carcinoma, CGH, comparative genomic hybridization,
FISH, fluorescence in situ hybridization, SKY, spectral karyotyping, FS, fragile site, BFB,
breakage– fusion –bridge, apc, aphidicolin
Address all correspondence to: Dr. Nicholas C. Popescu, 37 Convent Drive MSC 4262,
Building 37, Room 4128B, Bethesda, MD 20892-4262, USA. E-mail: popescun@dc37a.
nci.nih.gov
Received 18 June 2003; Revised 7 July 2003; Accepted 18 July 2003.
Copyright D 2003 Neoplasia Press, Inc. All rights reserved 1522-8002/03/$25.00
Neoplasia . Vol. 5, No. 5, September/October 2003, pp. 390–396 390
www.neoplasia.com
RESEARCH ARTICLE
of HCC cell lines showed both DNA copy number gains and
losses of the long arm of chromosome 5 [12]. The minimal
region of gain at 5q31 overlaps with the location of the
common fragile site (FS) FRA5C and the locus of the SMAD5
gene. The role of the Smad proteins in cancer and the
association of FS with sites of chromosomal breakage in
tumors prompted us to examine whether alterations in the
SMAD5 gene were present in human HCC and whether
these were associated with the region of FRA5C.
Materials and Methods
HCC Cell Lines
Huh-6, Huh-7, HLF, HLE, Hep3B, Hep-40, HepG2, Fo-
cus, 7703K, SK-Hep-1, PLC/PRF/5, and the six SNU lines
were obtained from the American Type Culture Collection
(Rockville, MD), or kindly provided by Dr. Curtis Harris
(National Cancer Institute, Bethesda, MD). These cell lines
were previously analyzed by CGH and their hepatitis B virus
(HBV) status was known [12]. Five cell lines (7703, SK-Hep-
1, HepG2, Huh-7, HLF, and HLE) were negative for HBV
[12]. Cells were cultured in DMEM/F12 medium supple-
mented with 10% fetal bovine serum and antibiotics.
Northern Blot Analysis
Total RNA was extracted from HCC cell lines using Trizol
reagent (Invitrogen/Life Technologies, Carlsbad, CA). Nor-
mal human liver total RNA was purchased from Stratagene
(La Jolla, CA; cat no. 735018). Twenty-microgram aliquots of
each RNA sample were denatured in 50% formamide/6.5%
formaldehyde and resolved on 1% agarose/4-morpholine-
propanesulfonic acid/formaldehyde gels and transferred to
nylon membranes. A human SMAD5 cDNA clone
(no. 262686; IMAGE Consortium, http://image.llnl.gov)
was purchased from the American Type Culture Collection
(Manassas, VA). A 1-kb HindIII fragment at the 3V end of the
insert (corresponding to nt 984–1969 of GenBank U59913)
was labeled with [a-32P]dCTP by the random primer method
and hybridized to Northern blots as previously described [5].
As a control for loading, the blots were rehybridized to a
polymerase chain reaction (PCR)–generated probe for the
murine ribosomal protein L19 cDNA (nt 120–495 of Gen-
Bank NM_009078). The blots were exposed to X-ray film,
the autoradiograms were scanned on an HP Scanjet 4400c
(Hewlett Packard, Palo Alto, CA), and the SMAD5 and L19
bands were quantified using ImageQuant software (Mole-
cular Dynamics, Sunnyvale, CA).
Southern Blot Hybridization
Genomic DNA was purified from HCC cell lines by a
modification of the original method [13]. Genomic DNA from
normal human fibroblasts was obtained from the Coriell
Institute for Medical Research (Camden, NJ; cat no.
NA00726). Five-microgram aliquots of DNA were digested
with HindIII and fractionated on a 1% agarose/TAE gel. The
DNA was blotted onto a nylon membrane and hybridized to
the SMAD5 cDNA probe as indicated above. As a control for
the copy number of chromosome 5, the blot was rehybridized
to a 32P-labeled, PCR-generated probe for the occludin gene
(nt 179471–180050 of GenBank AC044797) located at 5q12.
Semiquantitative PCR Analysis
Genomic DNA samples from 17 primary HCC and match-
ing normal liver tissues [4] were subjected to multiplex PCR
analysis. Primer pairs from the 3V UTRs of the human
SMAD5 cDNA (5V-CCAGTTCAGAAATTTGGCATTG and
5V-TGGTGGGACAAAGAAA CTGG; nt 1761–1782 of Gen-
Bank U59913) and of the human occludin cDNA (5V-GAAGC-
CAAACCTCTGTGAGC and 5V-GAAGACATCGTCTGGG-
GTGT; nt 1825–2053 of GenBank U49184), an internal
control, were selected using the Primer3 program of the
Whitehead Institute/MIT Center for Genome Research
(http://www-genome.wi.mit.edu). Amplifications were per-
formed using 50 ng of genomic DNA, 10 pmol of each primer,
1.0 U of Taq DNA polymerase (Promega, Madison, WI), 300
mM dNTPs, 1.5 mM MgCl2, and 1/10 vol of 10  PCR buffer
(10 mM Tris–HCl, pH 9.0, 50 mM KCl, and 0.1% Triton
X-100) in a final reaction volume of 30 ml. The optimized
conditions for quantitative PCR conditions were as follows:
an initial denaturation for 5 minutes at 95jC followed by 25
cycles of 94jC for 50 seconds, 60jC for 40 seconds, 72jC
for 50 seconds, and a terminal extension for 5 minutes at
72jC. The PCR products were loaded on 6% acrylamide/
TBE precast gels (BMA, Rockland, ME) and electrophoresed
at 180 V for 1 hour in 0.5  TBE buffer. The PCR products
were visualized by ethidium bromide staining and photo-
graphed under UV transillumination. The individual bands
were quantified by densitometry (Kodak Gel Logic 100
Image System, Rochester, NY) and the relative intensities
of the SMAD5 and occludin bands were calculated.
Induction of FS FRA5C
For the expression of FRA5C, synchronized cultures of
human lymphocytes derived from two healthy donors were
Table 1. Number of SMAD5 FISH Signals and of Normal Chromosome 5 in
HCC Cell Lines.
Cell Line SMAD5 Chromosome 5
PLC/PRF/5 2 2
Focus 3 2
HepG2 2 2
Hep3B 2 2
Hep-40* 2 2
HLE 4 2
HLF 3 1
SNU182 4 4
SNU387 3 3
SNU398 3 1
SNU423 5 5
SNU449 2 2
SNU475 3 1
7703K 4 1
SK-Hep-1 3 3
Huh-7 3 2
*Besides fluorescent SMAD5 signals on normal chromosomes 5, Hep-40
cells carry multiple additional SMAD5 signals located on rearranged de-
rivative chromosomes that contain materials from chromosome 5.
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used. Cells were treated with aphidicolin (apc) (0.2–0.4 mM;
Sigma, St. Louis, MO) in DMSO or in ethanol (0.2%) for 26
hours, and subsequently exposed to caffeine (2.2 mM; Sig-
ma) for 6 hours prior to chromosome preparation as previ-
ously described [14]. Metaphase spreads were prepared
after 3 to 4 hours of colcemid (50 mg/ml) treatment by
standard KCl hypotonic treatment, acetic acid–methanol
fixation, and air-dried slide preparation.
Molecular Cytogenetic Analysis
Chromosomes prepared from exponentially growing HCC
cultures were used for fluorescence in situ hybridization
(FISH) and SKY. Chromosome preparations derived from
synchronized normal human peripheral lymphocytes were
used for CGH analysis of HCC genomic DNA. Metaphase
spreads from synchronized, apc/caffeine–treated normal
human peripheral lymphocytes were used for FISH visuali-
zation of SMAD5 signals relative to FRA5C. In all FISH
experiments regardless of the target chromosome prepara-
tions, a P1-derived artificial chromosome (PAC) genomic
clone containing the SMAD5 gene labeled with digoxigenin,
and biotinylated centromeric and whole chromosome 5
painting probes were used. The SMAD5 signals were local-
ized on look-up table (LUT)-inverted and contrast-enhanced
Figure 1. Two-color FISH detection of chromosome 5 (yellow, biotin-labeled) and the SMAD5 gene (red, digoxigenin-labeled) in metaphase chromosome spreads
from human HCC cell lines SNU449 (a), SNU398 (b), HLF (c), and 7703K (d).
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digital images of DAPI-counterstained G-like banded chro-
mosomes with approximately 400 band resolution. The pro-
cedures used for CGH, SKY, and FISH were previously
described in detail [12,15,16].
Results
A recurrent CGH pattern of DNA copy number gains and
losses of chromosome 5 was reported previously in HCC cell
lines [12]. In addition, our previous chromosome painting and
G-banding analysis as well as the ongoing SKY investigation
of HCC cell lines showed a variety of changes involving
chromosome 5q [16]. To determine the extent and nature of
chromosome 5 reorganization and its impact on the copy
number of the SMAD5 gene, FISH was performed with a
SMAD5 genomic probe and chromosome 5 painting probe in
16 HCC cell lines. All lines are aneuploid with a near-triploid
or near-tetraploid chromosome number. In eight cell lines, an
equal number of FISH signals for SMAD5 and normal
chromosomes 5 were observed (Table 1). An example of a
metaphase derived from SNU449 cells with normal chromo-
some 5 and signals for SMAD5 is shown in Figure 1a. In
metaphases from the Focus, Hep-40, HLE, HLF, Huh-7,
SNU398, SNU475, and 7703K cell lines, the signals for
SMAD5 gene exceeded the number of normal chromosome
5 and were also localized on abnormal chromosome 5. None
of the cell lines had fewer SMAD5 signals than copies of
chromosome 5 (Table 1).
Structural changes involving chromosome 5 consisted of
interstitial deletions, unbalanced translocations, and the
formation of isochromosomes containing the whole chromo-
some 5q or segments of chromosome 5q. Isochromosomes
carrying SMAD5 signals were identified in HLF, HLE, and
SNU423 cells, whereas deletions and translocations with the
breakpoints near the SMAD5 locus as indicated by the FISH
signal were found in Focus, Huh-7, SNU398, and 7703K
cells. Representative examples of chromosome 5 alterations
found in HCC cell lines are shown in Figure 1; a translocation
in SNU398 cells with the breakpoint near SMAD5 locus
(Figure 1b), an isochromosome 5q in HLF cells (Figure 1c),
and multiple dispersed segments of chromosome 5, carrying
SMAD5 signals in 7703K cells (Figure 1d), are shown.
In Hep-40 cells, one of four cell lines exhibiting DNA copy
number gain in the distal region of chromosome 5q, a high-
level SMAD5 amplification was detected by FISH with a
genomic probe (Figure 2). In interphase nuclei, multiple
SMAD5 signals were visible, and scoring of over a hundred
nuclei gave an average of 13 to 17 signals per cell (Figure
2a). In all 50 metaphase spreads examined from Hep-40
cells, two pairs of SMAD5 signals were located on normal
chromosome 5, and an orderly array of signals was clustered
on an abnormal chromosome (Figure 2b). CGH profile
showed that the region of gain was confined to a single
band, 5q31, where the SMAD5 gene is localized (Figure 2c).
SKY analysis demonstrated that the abnormal chromosome
carrying multiple copies of SMAD5 gene is a complex
rearrangement involving chromosomes 4, 5, 15, 18, and 19
(Figure 2d). The identified region of amplification (Figure 2d)
was larger than the band 5q31, and had an abnormal
Figure 2.Multiple SMAD5 signals in interphase nuclei from HCC cell line Hep-40 (a); an array of SMAD5 fluorescent signals localized on an abnormal chromosome
containing an abnormally banded region (b); and FISH localization confirming local high-level amplification of the region of chromosome 5q31 harboring the
SMAD5 gene as indicated by CGH (c). SKY analysis enabled the characterization of the abnormal chromosome harboring SMAD5 amplification (d) as a complex
rearrangement involving chromosomes 4, 5, 15, 18, and 19.
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G-banding pattern typical for chromosomal segments har-
boring gene amplification [17].
Because SMAD5 and FRAC5 colocalize at region 5q31
and, a in few cases, the initiation of gene amplification in
cancer cells was shown to occur at FS, chromosomes
derived from normal lymphocytes cultures exposed to apc
to induce the expression of FS were hybridized with the
SMAD5 probe. Although FRA5C is not among the most
frequently expressed FS, a sufficient number (25) of meta-
phases expressing FRA5C and showing informative signals
were examined. The fluorescent signal for SMAD5 localized
either centromerically or telomerically, or was divided by
the gap of FRA5C in 17, 6, and 2 metaphases, respectively
(Figure 3, a–c).
Southern blotting was performed to confirm that the
SMAD5 gene was amplified in Hep-40 cells. As a control
for chromosome 5 copy number, the blot was also hybridized
to a probe for the occludin gene, located at 5q12, outside of
the amplified region. The relative intensity of the 8-kb
SMAD5 HindIII band was considerably greater in DNA from
the Hep-40 cell line, confirming the high degree of amplifi-
cation of the gene (Figure 4).
To see whether the SMAD5 gene is altered in primary
HCC, we examined 17 specimens. Because the genomic
DNA available was not sufficient for Southern blotting, the
primary tumors and matching normal liver tissues were
screened by semiquantitative PCR. In one tumor, a 50%
decrease in the intensity of the SMAD5 PCR product was
observed and, in another, a 40% increase was seen com-
pared to an internal control and normal DNA counterparts,
whereas in 15 tumors, no changes were detected. Repre-
sentative examples are shown in Figure 5.
To correlate the copy number of SMAD5 signals with the
expression of the gene, the levels of SMAD5 mRNA in the
HCC cell lines were examined by Northern blotting. The
SMAD5 probe hybridized to a major band of f7.5 kb and
a minor band of f4 kb (not shown), as reported by others
[18]. The size of the larger band is consistent with the
presence of a 5.2-kb 3V-untranslated region in the transcript
(GenBank BK001394). SMAD5 mRNA was detected in all of
the HCC cell lines and, in most cases, the levels were
roughly similar to that found in normal liver, when normalized
to the amount of ribosomal protein L19 mRNA (Figure 6).
However, the SMAD5 mRNA level was 2.5-fold higher in the
Hep-40 line that showed amplification of the gene, indicating
that the increased gene dosage was associated with over-
expression of the gene.
Discussion
In this analysis, we report genomic changes involving a
region of chromosome 5 and changes in the SMAD5 gene
expression, which may be both relevant in the pathogenesis
of human HCC. We demonstrated deletions and unbalanced
Figure 3. FISH with the SMAD5 probe on chromosomes from apc-treated normal lymphocytes, localizing the SMAD5 signal within the domain of the FRA5C FS: on
the proximal end of the gap (a), split by the break (b), and on the distal end of the gap (c).
Figure 4. Southern blot analysis of SMAD5 gene amplification. A Southern
blot of HindIII-cut genomic DNA from normal human fibroblasts and the Hep-
40 HCC cell line was hybridized to the SMAD5 cDNA probe (top) and the
occludin (OCLN) probe (bottom). The SMAD5 and OCLN probes hybridized
to single HindIII bands of 8 and 1.7 kb, respectively.
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translocations with breakpoints near SMAD5 locus, the
recurrent formation of isochromosome 5q leading to selec-
tive loss and gain of 5p and 5q, and the intrachromosomal
amplification of SMAD5 gene at the FS FRA5C indicating
that this locus is a frequent target in HCC. However, CGH
analyses performed by us and others have shown that
chromosomal regions carrying other Smad genes (SMAD1,
SMAD2, SMAD4, SMAD7, and SMAD9) are underrepresent-
ed in the majority of the cell lines examined here [12].
Over the last several years, the most frequently ex-
pressed, common apc-sensitive FS have been cloned and
found to be the sites of deletion and amplification of cancer-
related genes, as well as of integration of oncogenic viruses.
Deletions of two tumor-suppressor genes located at com-
mon FS, FHIT at FRA3B and WWOX at FRA16D, have
been observed in several types of cancer as well as numer-
ous integrations of human papilloma viruses at FS in cervical
carcinoma (reviewed in Refs. [19–23]).
Gene amplification is a common alteration in cancer cells,
and like other structural changes, it is associated with ge-
nomic instability and frequently involves oncogenes whose
increased expression confers a selective advantage on tumor
cell growth [1,24]. Thus far, a few cases with a relatively low
level of gene amplification mediated by breakage–fusion–
bridge (BFB) cycles at FS have been demonstrated—the
MET oncogene in gastric cancer through FRA7G and theRIN
gene in oral cancer through FRA11B [25,26]. More recently,
DNA amplification through BFB cycles initiated by spontane-
ous telomere loss was shown in a human tumor cell line
having a herpes virus thymidine kinase selectable marker
integrated adjacent to the telomere on amarker chromosome
16 [27]. Chromosomal FS are regions prone to breakage,
instability, and recombination [19–23]. FRA5C, although
rather infrequently expressed, is no exception [28].
The marker chromosome in Hep-40 cells that carries
multiple copies of SMAD5 is a complex rearrangement
involving several chromosomes. Similar large markers were
also observed in human tumor cells, and in rodent cells with
amplification of drug resistance genes [25–27,29]. Such
markers, which typically exhibit an abnormal banding pattern
or homogeneously staining regions, are often apparent in
tumor cells and may contain two or more amplified genes,
frequently oncogenes. In a well-known breast carcinoma cell
line SK-BR-3, we identified a marker originating from four
chromosomes and containing multiple copies of the ERBB-2
and MYC oncogenes on both chromosome arms [30]. The
abnormal chromosome carrying the SMAD5 amplicon in
Hep-40 tumor cells originated from five different chromo-
somes. The significant level of SMAD5 amplification in Hep-
40 cells makes it difficult to determine how the amplification
process was initiated. However, FISH analysis clearly
showed that SMAD5 is located within FRA5C.
This is consistent with other reports showing that FS could
initiate gene amplification through BFB cycles [25–27,29].
Figure 5. Semiquantitative PCR analysis of SMAD5 gene in primary tumors. DNA from two primary HCC, Cases 2 and 20, displayed a 50% decrease and a 40%
increase in the SMAD5 PCR products, respectively, compared to an internal control and normal DNA counterparts. Case 14 was similar to the remaining tumors,
showing no difference between SMAD5 and OCLN.
Figure 6. SMAD5 expression in HCC cell lines. Northern blots of total RNA from normal liver tissues and HCC cell lines were hybridized to the SMAD5 cDNA
probe, and the major SMAD5 transcript of 7.5 kb is shown. As a control for loading, the blots were rehybridized to a mouse ribosomal protein L19 probe. The
relative SMAD5 mRNA levels for each sample were calculated as the ratio of the intensities of the SMAD5 and L19 bands, divided by the ratio in normal liver cells.
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The complexity of the chromosome marker carrying the
SMAD5 amplicon suggests breakage and interchromosome
exchanges at two other FS on chromosome 5q and at non-FS
regions. Recently, coamplification of the MET oncogene
with three candidate tumor-suppressor genes was demon-
strated in the GTL-16 gastric cancer cell line [31]. The size of
the 5q amplicon in Hep-40 cells, however, has not been
determined, and whether other genes are coamplified with
SMAD5 is not known. No obvious candidate protooncogenes
that could drive amplification map to the 5q31 region.
Our results strongly suggest that SMAD5 does not func-
tion as a tumor suppressor in HCC, as its expression is either
maintained or upregulated by an increase in gene copy
number or another mechanism. Localization of SMAD5 to a
region at 5q31 commonly deleted in myeloid tumors indicat-
ed that it might be a tumor-suppressor gene, but no inacti-
vating mutations have been found in the SMAD5 gene when
a number of different human primary tumors and cancer cell
lines were analyzed [18,32,33]. In addition, increased ex-
pression of Smad5 was observed in colorectal cancer by
immunohistochemistry [34,35]. Smad5 is activated by mem-
bers of the bone morphogenetic protein (BMP) branch of the
TGF-b superfamily [9]. The role of BMPs in the growth and
differentiation of normal liver cells and in hepatocarcino-
genesis has not been extensively studied. The HBV pX
oncoprotein was found to enhance TGF-b and BMP-2 sig-
naling by interacting with Smad4 [36]. Whether HBV infection
affects the activity of Smad5 remains to be determined.
Further investigations are needed to determine how alter-
ations in the levels of Smad5 protein and its binding partners
contribute to the process of hepatocarcinogenesis.
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